ABOUT this BLOG and How to use it

WELCOME to Stu's Views & MS News. A product of MS Views and News, a Not-for-Profit [501c3] organization. Founded in 2008, we provide educational Multiple Sclerosis information via live seminars and via the internet.

Key-Notes: Our live seminars average approx 60 people per educational program. Our blog is visited over 2900 times per week and our website is visited by thousands each month.

Register at our website to receive our globally transmitted Multiple Sclerosis e-newsletter, currently being received in (90) Countries.

On this blog see our Directory, Archives, recent Blog Posts & so much more. Use the Blog Search box (enter a keyword). See our Facebook information AND Links to other MS Organizations & bloggers. Scroll through entire page, to find information that could EMPOWER You. At the Bottom of this page, see informational videos and some for fun.

Disclaimer: "Stu's Views & MS News" / 'MS Views and News' does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Like this blog? - CLICK "LIKE"

Thursday, December 8, 2011

STOPPING MS IN ITS TRACKS, RESTORING LOST FUNCTION, ENDING MS FOREVER



STOPPING MS IN ITS TRACKS
New therapies showing positive results -- Several late-stage, phase III clinical trials in relapsing MS are making their way toward seeking marketing approval. These include oral teriflunomide, oral BG-12, and intravenous alemtuzumab. An application was accepted by the FDA to review teriflunomide for marketing approval.

Speeding diagnosis – An international panel revised and simplified the “McDonald Criteria” commonly used to diagnose MS, which is expected to reduce the emotionally wrenching wait for a confirmed answer to possible MS symptoms.

Early results support research of parasitic worms to treat MS -- At least two published studies reported results related to parasitic worms, called helminths, and their possible implications for treating MS. Further study, including the second phase of the clinical trial supported by the National MS Society, should determine whether a “probiotic” treatment approach using relatively harmless parasitic worms to alter immune activity will benefit people with MS.
MUCH more to read.  CONTINUE by clicking here


..
..Comments for each blog posting are always appreciated. 
     Please use the link found below, to leave comments..
All comments are moderated to reduce SPAM and bad language
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
 Click to: REGISTER For our MS weekly e-Newsletter
"Providing You with 'MS Views and News', IS What We Do"   ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
Help us to educate $ DONATE NOW PLEASE $

"MS Views and News"  is a 501©(3) Not-For-Profit organization
 as recognized by the Internal Revenue Service

All contributions are tax deductible to the fullest extent allowed by law
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
..............................

0 comments: